BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32299110)

  • 1. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.
    Ilanchezhian M; Khan S; Okafor C; Glod J; Del Rivero J
    Horm Metab Res; 2020 Aug; 52(8):588-597. PubMed ID: 32299110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
    Lodish MB; Stratakis CA
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary thyroid carcinoma in children: current state of the art and future perspectives.
    Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N
    J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hereditary medullary thyroid carcinoma.
    Pappa T; Alevizaki M
    Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary thyroid cancer: molecular factors, management and treatment.
    Pavlidis E; Sapalidis K; Chatzinikolaou F; Kesisoglou I
    Rom J Morphol Embryol; 2020; 61(3):681-686. PubMed ID: 33817709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).
    Castellone MD; Melillo RM
    Endocr Relat Cancer; 2018 Feb; 25(2):T105-T119. PubMed ID: 28931560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
    Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
    Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma: a review on ethical considerations in treatment of children.
    Nozhat Z; Hedayati M
    J Pediatr Endocrinol Metab; 2016 Jun; 29(6):633-9. PubMed ID: 26974132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on therapy for medullary thyroid cancer in 2021.
    Puerto M; Borson-Chazot F; Tabarin A
    Ann Endocrinol (Paris); 2022 Apr; 83(2):114-118. PubMed ID: 34921811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical and clinical strategies in the management of thyroid medullary carcinoma in children with and without ret proto-oncogene mutations.
    Boybeyi-Türer Ö; Vurallı D; Karnak İ; Gönç N; Yalçın EŞ; Orhan D; Kandemir N; Tanyel FC
    Turk J Pediatr; 2016; 58(4):436-441. PubMed ID: 28276221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
    Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
    Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
    Yeganeh MZ; Sheikholeslami S; Hedayati M
    Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.
    Amodru V; Taieb D; Guerin C; Romanet P; Paladino N; Brue T; Cuny T; Barlier A; Sebag F; Castinetti F
    Endocrine; 2020 Sep; 69(3):496-503. PubMed ID: 32388798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.